MRNA Jan 2026 130.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 02:58PM EDT. Market open.
Loading interactive chart...
- Investor's Business Daily
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
- ACCESSWIRE
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) ...
- Investor's Business Daily
Is Moderna Stock A Buy As The U.S. Government Mulls Its Bird Flu Vaccine?
Moderna stock is on the rise again as investors focus on the potential need for a bird flu vaccine. Is MRNA stock a buy right now?
© 2024 Yahoo. All rights reserved.